• Seven MACs have now published or confirmed payment rates for RECELL®, providing physicians with confidence of payment
• Clinical data and reimbursement align to reinforce the full value of RECELL for patients, clinicians, and hospitals
• Focusing on ~200 key burn and trauma centers, covering the highest-volume accounts

AVITA Medical Inc. presented its Q3 2025 financial and business update, emphasizing the significant progress made in reimbursement for its RECELL® product. The company announced that all seven Medicare Administrative Contractors (MACs) have now published or confirmed payment rates for RECELL®, providing physicians with confidence in receiving payment when using the product. This development aligns with the clinical data, demonstrating improved outcomes and shorter hospital stays for patients. AVITA is now focused on approximately 200 key burn and trauma centers, covering the highest-volume accounts and active in around 90% of their target sites. This strategic focus, along with the expanding utilization and patient access, is expected to drive significant and scalable growth potential for the company. Despite a year-over-year decrease in Q3 revenue, AVITA has reduced operating expenses by 24% through disciplined cost management. The company also reported improved net cash use, underscoring its improving cash efficiency. Looking ahead, AVITA is committed to driving disciplined execution, refining its commercial focus, and positioning the company for growth in 2026.

AVITA is focused on driving disciplined execution, refining its commercial focus, and positioning the company for growth in 2026.